|本期目录/Table of Contents|

[1]张沛,周昱,何旭,等.咪唑立宾治疗儿童紫癜性肾炎的疗效与安全性[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):6-12.[doi:10.3969/j.issn.1672-271X.2022.01.002]
　ZHANG Pei,ZHOU Yu,HE Xu,et al.Effect and safety of mizoribine on Henoch-Schnlein purpura nephritis in children[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):6-12.[doi:10.3969/j.issn.1672-271X.2022.01.002]
点击复制

咪唑立宾治疗儿童紫癜性肾炎的疗效与安全性()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第24卷
期数:
2022年1期
页码:
6-12
栏目:
临床研究
出版日期:
2022-02-20

文章信息/Info

Title:
Effect and safety of mizoribine on Henoch-Schnlein purpura nephritis in children
作者:
张沛; 周昱; 何旭; 史卓; 孙涛; 杨晓; 匡仟卉柠; 姚俊; 方香; 高远赋; 高春林; 夏正坤
作者单位：210002南京，东南大学医学院第二临床医学院（东部战区总医院）儿科（张沛、周昱、何旭、史卓、孙涛、杨晓、匡仟卉柠、姚俊、方香、高远赋、高春林、夏正坤）
Author(s):
ZHANG Pei;  ZHOU Yu;  HE Xu;  SHI Zhuo;  SUN Tao; YANG Xiao;  KUANG Qian-hui-ning;  YAO Jun;  FANG Xiang;  GAO Yuan-fu;  GAO Chun-lin;  XIA Zheng-kun
（Department of Paediatrics, The Second School of Clinical Medicine, Southeast University/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China）
关键词:
咪唑立宾; 紫癜性肾炎; 儿童; 疗效
Keywords:
mizoribine;  Henoch-Schnlein purpura nephritis;  children;  clinical effect
分类号:
R726.9
DOI:
10.3969/j.issn.1672-271X.2022.01.002
文献标志码:
A
摘要:
目的探讨咪唑立宾（MZR）治疗儿童紫癜性肾炎（HSPN）的疗效与安全性。方法选择2016年1月至2017年10月东部战区总医院儿科收治的儿童HSPN55例，按照随机数字分组法随机分为2组：强的松（PDN）与MZR联合治疗组（联合组，n=38）和MZR单药治疗组（单药组，n=17）。分析2组患儿的随访3个月、6个月、12个月和24个月实验室检查结果、预后和不良反应。结果联合组6个月、12个月和24个月ALB水平高于基线值（P<0.05）；单药组12个月和24个月ALB水平高于基线值（P<0.05）；联合组6个月、12个月和24个月尿蛋白定量水平低于基线值（P<0.05，P<0.01）；单药组12个月和24个月尿蛋白定量水平低于基线值（P<0.05，P<0.01）；联合组3个月、6个月、12个月和24个月尿NAG酶水平低于基线值（P<0.01）；单药组6个月、12个月和24个月尿NAG酶水平低于基线值（P<0.05，P<0.01）；联合组6个月、12个月和24个月尿RB蛋白水平低于基线值（P<0.05，P<0.01）；单药组12个月和24个月尿RB蛋白水平低于基线值（P<0.01）。预后分级：A级和总体预后分级联合组高于单药组（97.37% vs 82.35%,P<0.05），B级预后分级联合组低于单药组（2.63% vs 17.65%,P<0.05）。联合组尿蛋白消失比例明显高于单药组（P<0.01）。联合组血WBC升高比例高于单药组（86.84% vs 58.82%,P<0.05），呼吸道感染次数高于单药组（63.16% vs 23.53%,P<0.05），HSP复发次数低于单药组（2.63% vs 17.65%,P<0.05）。结论MZR治疗儿童HSPN有效性和安全性较高，PDN联合MZR治疗HSPN的临床效果高于单药MZR，且长期预后好于单药MZR。
Abstract:
ObjectiveTo investigate the efficacy and safety of mizoribine (MZR) in children with Henoch-Schnlein purpura nephritis (HSPN).MethodsFrom January 2016 to October 2017, 55 cases of children with HSPN admitted to the Department of Paediatrics of Jinling Hospital were analyzed. According to the treatment, all patients were divided into prednisone (PDN) and MZR combined treatment groups (PDN+MZR group, n=38) and MZR monotherapy group (MZR group, n=17). The laboratory test results of 3 mouths, 6 mouths, 12 mouths and 24 mouths follow-up time, prognosis and adverse reactions of the two groups of children were analyzed.ResultsAt the follow-up time of 6 mouths, 12 mouths and 24 mouths, the albumin (ALB) levels in PDN+MZR group were higher than the baseline (P<0.05). At 12 mouths and 24 mouths time, the ALB levels in MZR group were higher than the baseline (P<0.05). At 6 mouths, 12 mouths and 24 mouths time, urine protein level in PDN+MZR group were lower than the baseline (P<0.05, P<0.01). At 12 mouths and 24 mouths time, urine protein level in MZR group were lower than the baseline (P<0.05, P<0.01). At 3 mouths, 6 mouths, 12 mouths and 24 mouths time, the urinary NAG enzyme level in PDN+MZR group were lower than the baseline (P<0.01). At 6 mouths, 12 mouths and 24 mouths time, the urinary NAG enzyme level in MZR group were lower than the baseline (P<0.05, P<0.01). At 6 mouths, 12 mouths and 24 mouths time, the urinary RB protein levels in PDN+MZR group were lower than the baseline (P<0.05, P<0.01). At 12 mouths and 24 mouths time, the urine RB protein level in the MZR group was lower than the baseline (P<0.01). A prognosis classification and overall prognosis classification in PDN+MZR group was higher than that in MZR group (97.37% vs 82.35%, P<0.05). B prognosis classification in PDN+MZR group was lower than that in MZR group (2.63% vs 17.65%, P<0.05). The percentage of urinary protein disappearance in PDN+MZR group was higher than that in MZR group (P<0.01). The proportion of increased blood WBC in the PDN+MZR group was higher than that in MZR group (86.84% vs 58.82%, P<0.05). The number of respiratory infections in the PDN+MZR group was higher than that in MZR group (63.16% vs 23.53%, P<0.05). And the number of HSP recurrences in the PDN+MZR group was lower than that in MZR group (2.63% vs 17.65%, P<0.05).ConclusionMZR is shown an effectiveness and safety in the treatment of children with HSPN. The clinical effect of PDN combined with MZR in the treatment of HSPN is higher than MZR monotherapy. And the long-term prognosis is better than MZR monotherapy.

参考文献/References:

[1]Ozen S, Acar-Ozen NP. Recent advances in childhoodvasculitis[J]. Curr Opin Rheumatol，2017，29(5): 530-534.
[2]Buscatti IM, Casella BB, Aikawa NE，et al. Henoch-Schnlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center[J]. Clin Rheumatol，2018，37(5): 1319-1324.
[3]Yel S, Dursun I, Pinarba �瘙 塂 i AS，et al. Patient Outcomes of Henoch-Schnlein Purpura Nephritis According to the New Semiquantitative Classification[J]. Fetal Pediatr Pathol，2020，39(5): 381-389.
[4]Sugimoto H, Matsuno S, Yamanaka N，et al. Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis[J]. CEN Case Rep，2020，10(1):46-52.
[5]Sugimoto H, Matsuno S, Yamanaka N，et al. Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis[J]. CEN Case Rep，2021，10（1）：46-52.
[6]Kagawa H, Hiromasa T, Yamanaka R，et al. The first year results of mizoribine tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis[J]. Clin Exp Nephrol，2018，22(6)：1371-1378.
[7]Ikeda K, Watanabe K, Hirai T，et al. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies[J]. Intern Med，2017，56（10）：1147-1152.
[8]Izumi Y, Nakaoka K, Kamata M，et al. Steroid-resistant protein-losing gastroenteropathy complicated with Sjgren’s syndrome successfully treated with mizoribine[J]. Mod Rheumatol，2018，28(4): 716-720.
[9]Liu L, Ren B, Zhang H，et al. Population Pharmacokinetic Analysis of Mizoribine in Chinese Renal Transplant Recipients[J]. Transplant Proc，2018，50(8): 2392-2397.
[10]中华医学会儿科学分会肾脏学组. 紫癜性肾炎诊治循证指南(2016) [J]. 中华儿科杂志，2017，55（9）：647-651.
[11]Feng D, Huang WY, Hao S，et al. A single-center analysis of Henoch-Schonlein purpura nephritis with nephrotic proteinuria in children[J]. Pediatr Rheumatol Online J，2017，15(1)：15.
[12]Xia ZK, Gao YF, Rong LP，et al. Usefulness of mizoribine administration in children with frequently relapsing nephrotic syndrome, and the relationship between pharmacokinetic parameters and efficacy: a multicenter prospective cohort study in China[J]. World J Pediatr，2019，15(3)：262-269.
[13]KDIGO. Chapter 11: Henoch-Schonlein purpura nephritis[J]. Kidney International Supplements，2012，2(2): 218-220.
[14]Mima A. Efficacy of mizoribine and prednisolone combination therapy in adult patients with IgA vasculitis[J]. Rheumatol Int，2017，37(8): 1387-1393.
[15]Ikeda K, Watanabe K, Hirai T，et al. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies[J]. Intern Med，2017，56(10)：1147-1152.
[16]Natale P, Palmer SC, Ruospo M，et al. Immunosuppressive agents for treating IgA nephropathy[J]. Cochrane Database Syst Rev，2020，3(3)：CD003965. doi: 10.1002/14651858.CD003965.pub3.
[17]Kurokawa Y, Koike K, Kaida Y，et al. Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia[J]. CEN Case Rep，2019，8(3): 205-211.
[18]Kondoh T, Ikezumi Y, Yokoi K，et al. Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome[J]. Clin Exp Nephrol，2019，23(9)：1154-1160.
[19]Lee D, Kim HY, Lee JH，et al. Long-term Survival Analysis of Kidney Transplant Recipients Receiving Mizoribine as a Maintenance Immunosuppressant: A Single-Center Study[J]. Transplant Proc， 2019，51（8）：2637-2642.
[20]Huang Y, Han M, Yang D，et al. Comparative Study of Mizoribine and Mycophenolate Mofetil Combined with a Calcineurin Inhibitor-Based Immunosuppressive Regimen in Patients with Alternative Donor Hematopoietic Cell Transplantation[J]. Biol Blood Marrow Transplant，2020，26(9): 1663-1669.
[21]Mizutani A, Fujinaga S, Sakuraya K，et al. Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome[J]. Clin Exp Nephrol，2019，23(2)：244-250.
[22]Hama T, Nakanishi K, Ishikura K，et al. Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial) [J]. BMC Nephrol，2018，19(1): 223.
[23]Ren P, Han F, Chen L，et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schnlein purpura nephritis[J]. Am J Nephrol，2012，36(3)：271-277.
[24]涂娟，陈朝英. 以轻度蛋白尿为主要表现的儿童紫癜性肾炎临床分析[J]. 中华实用儿科临床杂志，2017，32(17): 1313-1315.
[25]Sakurai K, Kubo K, Kanda H，et al. Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide-resistant ANCA-associated glomerulonephritis[J]. Int J Rheum Dis，2017，20（12）：2214-2216.
[26]Ikeda Y, Fukunari K, Uchiumi S，et al. A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchange[J]. CEN Case Rep，2020，9(1): 42-47.
[27]Chen P, Xu X, Liu L，et al. Prediction of mizoribine pharmacokinetic parameters by serum creatinine in renal transplant recipients[J]. Eur J Clin Pharmacol，2019，75(3):363-369.
[28]Shi Y, Liu H, Chen XG，et al. Hyperuricemia in Living Donor Kidney Transplantation Patients During Mizoribine Administration Caused Mainly by Changes in Kidney Function[J]. Transplant Proc，2019，51(5): 1392-1396.
[29]Li SF, Gong MJ, Sun YF，et al. In Vitro and in Vivo Antiviral Activity of Mizoribine Against Foot-And-Mouth Disease Virus[J]. Molecules，2019，24（9）：1723. doi: 10.3390/molecules24091723.
[30]薛源，赵宇蕾，齐谢敏，等. 有限采样法估算肾病患儿口服咪唑立宾药时曲线下面积模型的建立与验证[J]. 医学研究生学报，2020,33(9）：968-973.

相似文献/References:

[1]张沛,周昱,高春林,等.咪唑立宾联合糖皮质激素治疗儿童IgA肾病的临床研究[J].医学研究与战创伤救治(原医学研究生学报),2022,24(4):356.[doi:10.3969/j.issn.1672-271X.2022.04.005]
　ZHANG Pei,ZHOU Yu,GAO Chun-lin,et al.Clinical research of mizoribine in the treatment of children with IgA nephropathy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(1):356.[doi:10.3969/j.issn.1672-271X.2022.04.005]

备注/Memo

备注/Memo:
基金项目：江苏省自然科学基金（BK20190251）；中国博士后基金资助项目（2018M643888）
更新日期/Last Update: 2022-02-21